Superficial thrombophlebitis in ipsilateral breast after COVID-19 vaccination

On December 2020, the US Food and Drug Administration issued the first emergency use authorization for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report development of superficial thrombophlebitis in...

Full description

Saved in:
Bibliographic Details
Published in:Radiology case reports 2022-08, Vol.17 (8), p.2883-2887
Main Authors: Aran, Shima, Kayder, Orest O., Chopra, Teena, Abujudeh, Hani
Format: Article
Language:English
Subjects:
Case Report
COVID
COVID19 vaccine
Mondor’s disease
mRNA vaccination
superficial thrombophlebitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On December 2020, the US Food and Drug Administration issued the first emergency use authorization for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report development of superficial thrombophlebitis in the ipsilateral breast of a 43-year-old female 7 days after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. Given that this is the first case of superficial thrombophlebitis in the breast shortly after mRNA vaccination for COVID-19 reported to our knowledge, we suggest that this may be a rare vaccine-related event.
ISSN:1930-0433
1930-0433
DOI:10.1016/j.radcr.2022.05.018